Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019

Valérie Taly's Biography



Valérie Taly, CNRS Research Director, Professor and Group leader Translational Research and Microfluidics, Université Paris Cité

V. Taly is a CNRS research director and group leader of the Translational Research And Microfluidics team within the clinical oncology research unit MEPPOT (personalized medicine pharmacogenomics and therapeutic optimization) in the Cordeliers Research Center (university Paris Cité). Her team performs interdisciplinary researches aiming at developing and validating microfluidic tools for cancer research in close collaboration with clinicians and researchers in oncology and toxicology. Since 2008, she developed droplet-based digital procedures for Cancer diagnosis. Recently, her research has been dedicated to the clinical validation of droplet-based microfluidics for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics. She is co-founder of EMULSEO (2018) and METHYS DX (2021) start up companies.

Valérie Taly Image

Tracking Circulating DNA for Cancer Patient Follow-Up

Wednesday, 30 October 2019 at 10:15

Add to Calendar ▼2019-10-30 10:15:002019-10-30 11:15:00Europe/LondonTracking Circulating DNA for Cancer Patient Follow-UpCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Tracking of circulating cell-free nucleic acids in body effluents has been greatly facilitated by recent technological developments including droplet-based digital PCR and optimized NGS. These technics now allow to reach unprecedented sensitivity and precision for rare sequences detection and quantification. Strategies allowing analysis of several genetic and epigenetic cancer-specific alterations have will be presented for the detection of tumor DNA in patient samples. Moreover to demonstrate the pertinence of such procedures to overcome clinical oncology challenges, the results of several clinical studies will be presented. In particular, we will illustrate the pertinence of these approaches to monitor circulating tumor DNA in plasma (so-called liquid biopsy) for the follow-up of patients with localized or advanced cancers.


Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com